Neurophet, a Korea-based artificial intelligence company specializing in brain disease diagnostics and therapeutics, said it will showcase its flagship neuroimaging analysis solutions at the upcoming Alzheimer’s Association International Conference (AAIC) 2025, to be held in Toronto, Canada, from July 27 to 31 (local time).

At the conference, Co-CEO Been Jun-kil will deliver a presentation titled “Neurophet in the Era of Alzheimer’s Paradigm Shift: Journey to IPO and Beyond,” highlighting the company’s growth trajectory and strategic vision.

Neurophet plans to debut its new software, Neurophet AQUA AD, a tool designed to quantitatively analyze MRI and PET brain images for monitoring Alzheimer’s drug prescriptions, treatment efficacy, and potential side effects. The solution supports precise imaging analysis throughout the administration of anti-amyloid antibody therapies.

With global pharmaceutical companies accelerating development of Alzheimer’s treatments such as Leqembi (ingredient: lecanemab) and Kisunla (ingredient: donanemab), which require careful monitoring of side effects, the demand for image-based biomarker solutions like Neurophet AQUA AD is growing rapidly.

The software’s ability to assess brain imaging biomarkers associated with treatment-related complications has attracted increasing global attention.

In addition to AQUA AD, Neurophet will also exhibit two of its core AI-powered platforms at the conference: Neurophet AQUA, for neurodegeneration analysis, and Neurophet SCALE PET, a PET image quantification solution.

Neurophet aims to leverage AAIC 2025 as a global business development platform, engaging in partnering discussions with multinational pharmaceutical companies and potential clients. The company also plans to meet with key opinion leaders in neurology to highlight the differentiated strengths of its products and explore new avenues for collaboration.

“Neurophet AQUA AD is gaining recognition as a key partner solution for companies in the brain imaging biomarker space,” Been said. “Through our participation at AAIC 2025, we intend to accelerate global partnerships and collaborative development involving our core product portfolio.”